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INTRODUCTION
Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic 
acid] is an anticonvulsant drug that is used for the 
treatment of a variety of neurological and psychiatric 
disorders1 such as partial epilepsy2,3,4,5,6, neuropathic 
pain associated with diabetic peripheral neuropathy7,8, 
post-herpetic neuralgia8,9, fibromyalgia10,11,12,13, gen-
eralized anxiety disorders14,15,16,17 and cancer pain2,18. 
Pregabalin is structurally related to Gabapentin 
(Figure 1). Both drugs are derivatives of the neu-
rotransmitter γ-aminobutyric acid (GABA)1,2,3.
It is an alpha-2-delta ligand that inhibits calcium 
currents via high-voltage-activated channels contain-
ing the a2d-1 subunit and reduces neurotransmitter 
(noradrenaline serotonin, dopamine and substance P) 
release in hyperexcited neurons leading to attenuation 
of postsynaptic excitability1,2. Pregabalin unlike other 
anxiolitic compounds does not bind directly to GA-
BA
A
, GABAB and benzodiazepine receptors. 
In addition, GABA metabolism is not affected 
either. Pregabalin also interacts with opioids, benzo-
diazepines, barbiturates and ethanol and so far it is 
thought that the potential for abuse of this drug is less 
than benzodiazepines potential. However, new evi-
dence may challenge the prevailing view19,20.
Despite its extended use, cytogenetic effect of 
pregabalin remained unknown. Previous studies sug-
gest that other compounds modulating GABA-ergic 
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neurotransmission including benzodiazepines exhibit 
statistically significant genotoxicity in human lym-
phocyte cultures21.
The aim of the present preliminary study was to 
investigate the in vitro effect of pregabalin on human 
cultured lymphocytes, by estimating sensitive cytoge-
netic indices as SCEs, PRI and MI. SCEs has been 
identified as one of the most sensitive indices among 
sensitive biomarkers of genotoxicity, such as chromo-
somal aberrations, comet assay and micronuclei. PRI 
and MI have been used as sensitive indicators for the 
evaluation of the cytostatic activity of various envi-
ronmental hazards or therapeutic agents (Mourelatos, 
1996).
MATERIALS AND METHODS
In vitro SCE and PRI assays. In this study, blood 
samples were given by two healthy donors 18 and 19 
years old, who were non-smokers, not receiving any 
drugs, not consuming considerable quantities of alco-
hol, or not having suffered any kind of infection for 
the last 15 days.
Human lymphocyte cultures were prepared by 
adding in 5 ml chromosome medium (RPMI-1640, 
Biochrome, supplemented with 20% fetal calf serum, 
0,63% L-glutamine, 0,63% penicillin/streptomycin 
and 2% phytohaemagglutinin) at the beginning of the 
culture life, the following:
•  11-12 drops of normal human heparinized whole 
blood
•  5μg/ml 5-Bromodeoxyuridine (BrdU) and
•  The pregabalin solutions (A=2,5μg/ml, B=5μg/
ml, C=10μg/ml, D=15μg/ml, E=30μg/ml, F=60μg/ml, 
G=120μg/ml and H=150μg/ml final concentrations 
per culture)
The concentrations ranging from C to G were equiva-
lent to the ones more commonly used in clinical prac-
tice (therapeutic doses per os: 150-600 mg/day). The 
cultures were incubated at 37o C for 72 hours in the 
dark to minimize photolysis of 5-Bromodeoxyuridine. 
Colchicine was added 2h before the collection of the 
cultures. The cells were then collected by centrifu-
gation and exposed to 0,075M KCl for 10 minutes. 
The hypotonic solution spreads the chromosomes and 
hemolyses the red blood cells. The pellet was fixed 
three times with methanol:acetic acid (3:1). Drops of 
concentrated suspension of cells were placed on mi-
croslides that allow to air dry. For SCE, PRI and MI 
analysis, the slides were stained by a modification of 
the fluorescence plus Giemsa procedure to obtain har-
lequin chromosomes21,,22.
Statistical Analysis. In order to estimate SCEs, 
30 suitably spread second division cells from each 
culture were blindly scored. For PRI calculation, 100 
cells in the first, second, third and higher divisions 
from each culture were blindly scored and the for-
mula: PRI=M1+2M2+3M3/100 was applied, where M1, 
M2 and M3 are the percent values of cells in the first, 
second, third and higher divisions, respectively. For 
MI analysis, 1000 nuclei were scored. MI=number of 
metaphases/total number of cells. For the statistical 
evaluation of the experimental data, Student’s t-test 
was performed to determine whether any SCE values 
differed significantly from the controls and the χ2-test 
was used for PRI and MI comparisons. The Pearson 
product moment correlation coefficient r was applied 
for calculating the correlation between SCEs, PRI and 
MI. A criterion for testing whether r differs signifi-
cantly from zero was used whose sampling distribu-
tion is Students test with n-2 degrees of freedom.
RESULTS
Table 1 illustrates the cytotoxicity of pregabalin, pre-
sented as dose- dependent increase of SCE frequency 
of the two donors’ cultured lymphocytes. This increase 
shows statistically significance (P < 0,001) at pregaba-
lin concentrations’ D-H, while a small decrease (not 
statistically significant) in SCE rate has been found at 
concentrations A and B. 
Figure 1.
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PRI of the lymphocytes, in Table 2, is decreased at 
concentrations A-H but this decrease becomes statis-
tically significant (P < 0,001) only at concentrations 
F-H. 
MI values, in Table 3, show a dose- depended 
deceased at concentrations B-F, and an insignificant 
increased at concentrations G and H. Furthermore, a 
correlation was observed (P < 0,001) between:
•  the magnitude of the SCE induction and the MI 
alterations 
•  the MI alterations and PRI alterations and
•  the magnitude of the SCE induction and the PRI 
alterations 
Table 1. Effect of Pregabalin on SCE frequency in human lymphocyte cultures.
Dosage (μg/ml) 1st donor 2nd donor
Control 8,21 8,33
A 2,5 8,19 8,31
B 5 8,13 8,27
C 10 9,56 9,67
D 15 10,45* 10,78*
E 30 11,21* 11,49*
F 60 12,01* 12,44*
G 120 13,19* 13,54*
H 150 15,46* 15,71*
*Statistically significant (p < 0,001) increase over the corresponding control (t-test).
Table 2. Effect of Pregabalin on PRI values in human lymphocyte cultures.
Dosage (μg/ml) 1st donor 2nd donor
Control 2,61 2,48
A 2,5 2,59 2,47
B 5 2,58 2,46
C 10 2,54 2,4
D 15 2,49 2,35
E 30 2,43 2,3
F 60 2,39 2,26
G 120 2,37 2,25
H 150 2,3** 2,21**
**Statistically significant (p < 0.001) decrease over the corresponding control (χ² test).
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DISCUSSION
Pregabalin, along with similarly- structured Gabapen-
tin, has a different mechanism of action in comparison 
to other known anticonvulsants. Multiple mechanisms 
of action have been proposed to describe the effect of 
this drug but so far these mechanisms have remained 
poorly understood1. It is also believed that pregaba-
lin probably shares common neural mechanisms with 
SSRIs and benzodiazepines23, which except for their 
therapeutic roles, affect the immune system as well. 
Further knowledge of the way pregabalin affects hu-
man DNA will provide us a better understanding of 
its mechanism of action. Besides, it concerns a con-
siderable number of patients since it is approved for a 
variety of diseases. 
The important therapeutic role of pregabalin and 
the lack of knowledge on its effect on human DNA 
motivated us to investigate another aspect of its ac-
tion by estimating sensitive cytogenetic indices such 
as SCEs, PRI and MI, in order to study the cytotoxic 
and cytostatic activity of pregabalin in vitro. 
The results show that pregabalin causes a dose-de-
pendent, statistically significant increase of SCEs fre-
quency from concentrations D-H, although it caused 
a small not statistically significant decrease of SCEs 
frequency at concentrations A and B. (Figure 2).The 
SCEs’ increase followed by an equally significant de-
crease of MI ( although it was observed a small in-
crease of MI at concentrations G and H, Figure 3) and 
also a decrease of PRI values (Figure 3) which was 
statistically significant only at concentration H in both 
of the two experiments. 
Living cells have the ability to excise and repair 
a large variety of damage on DNA. High SCE values 
could be due to a considerable number of DNA dam-
ages24 that could not be repaired before T lymphocytes 
reach S phase in vitro. An inability of the repair mech-
anisms to restore DNA damage could increase SCEs 
too21,22. So the statistically significant increase of SCE 
values on cultured lymphocytes caused by pregabalin, 
shows that pregabalin has valuable cytotoxic action at 
least in the above mentioned doses.
Although, in this experimental work, the decrease 
of SCE values at concentrations A and B of pregaba-
lin is not statistically significant, it should be further 
investigated because pregabalin in smaller doses may 
have a protective role on DNA molecule by the rein-
forcement of repair mechanisms or/and by the lack of 
pregabalin-induced DNA damage in small doses24. 
MI and PRI in small therapeutic doses show no 
statistically significant decrease (Figures 3, 4). These 
results suggest a noncytostatic behavior of pregabalin 
in these doses, at least in vitro. On the contrary, at con-
centrations D-F, the decrease of the MI index was sta-
tistically significant and the correlation between MI 
and PRI values is very strong, so pregabalin has a cy-
tostatic behavior in vitro at concentrations D-F. Inter-
estingly, though PRI (Figure 3) continues to decrease 
Table 3. Effect of Pregabalin on MI values in human lymphocyte cultures.
Dosage (μg/ml) 2nd donor 3rd donor
Control 43 39
A 2,5 42 38
B 5 41 36
C 10 37*** 33***
D 15 32*** 29***
E 30 28*** 25***
F 60 27*** 24***
G 120 28 25
H 150 30 27
***Statistically significant (p < 0.001) decrease over the corresponding control (χ² test).
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at concentrations G and H, MI presents an unexpected 
increase (Figure 4) at these concentrations, which is 
not statistically significant, but the correlation of these 
alterations between MI and PRI is very strong. At the 
same concentrations the correlation between MI-SC-
Es and PRI-SCEs is equally strong. This observation 
should be subject to further investigation as it is an 
unexpected result and it can provide us with further 
information about the way pregabalin affects DNA at 
the largest therapeutic doses approved. 
This preliminary study shows that pregabalin, a 
new drug, has a very interesting cytogenetic behavior 
that should be tested in more detail. Our next step then 
would be the examination of cytogenetic behavior of 
pregabalin in a larger amount of donors and in in vivo 
experiments. 
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ΠΕΡΙΛΗΨΗ: Σκοπός: Η πρεγκαμπαλινη είναι ανάλογο του γ-αμινοβουτιρικού οξέως. Συνδέεται σε μια επικουρική υποομάδα 
των ενεργοποιημένων από διαφορά δυναμικού διαύλων ασβεστίου στο κεντρικό νευρικό σύστημα, εκτοπίζοντας δραστικά 
την [3Η]-γκαμπαπεντίνη. Ενδείκνυται για την θεραπευτική αντιμετώπιση του νευροπαθητικού άλγους, της επιληψίας καθώς 
και του γενικευμένου άγχους.
Υλικό και Μέθοδος: Μελετήθηκε η επίδραση της πρεγκαμπανίλης in vitro στο ανθρώπινο DNA με τον υπολογισμό ευαίσθη-
των κυτταρογενετικών δεικτών. Οι χρωματιδιακές ανταλλαγές (Sister Chromatid Exchanges, SCEs) θεωρούνται ο πιο ευ-
αίσθητος δείκτης γονοτοξικότητας, ο δείκτης ρυθμού πολλαπλασιασμού (Proliferation Rate Index, PRI) ένας από τους πιο 
αξιόπιστους δείκτες κυτταροστατικότητας, ενώ ο μιτωτικός δείκτης (Mitotic Index, ΜΙ) δείχνει με ακρίβεια την κατάσταση 
του κυτταρικού πολλαπλασιασμού. Αρχικά παρασκευάστηκαν διαλύματα πρεγκαμπαλίνης 8 διαφορετικών συγκεντρώσεων 
(Α=2,5μg/ml,Β=5μg/ml,Γ=10μg/ml,Δ=15μg/ml,,Ε=30μg/ml, ΣΤ=60 μg/ml, Ζ=120 μg/ml, Η=150 μg/ml), μεταξύ των οποί-
ων οι συγκεντρώσεις από Γ εως Ζ είναι οι πιο συχνά χρησιμοποιούμενες στην κλινική πράξη. Τα διαλύματα προστέθηκαν 
σε καλλιέργειες λεμφοκυττάρων από περιφερικό αίμα δύο νεαρών υγειών αιμοδοτών. Μετά από 72 ώρες επώασης, με την 
κατάλληλη τεχνική τα καλλιεργημένα λεμφοκύτταρα επιστρώθηκαν σε αντικειμενοφόρους πλάκες, χρωματίστηκαν με την 
μέθοδο Fluorescence plus Giemsa και οι προαναφερθέντες δείκτες υπολογίστηκαν με το οπτικό μικροσκόπιο. 
Αποτελέσματα: Μετά την στατιστική επεξεργασία των αποτελεσμάτων διαπιστώθηκε ότι οι SCEs αυξάνονται ανάλογα με 
την συγκέντρωση της πρεγκαμπαλίνης στις πιο συχνά χρησιμοποιούμενες συγκεντρώσεις ενώ δεν φαίνεται να επηρεάζονται 
σημαντικά στις συγκεντρώσεις Α και Β. Οι ΜΙ και PRI παρουσιάζονται σημαντικά μειωμένοι στις συγκεντρώσεις Γ,Δ,Ε ενώ 
στην Ζ,Η ο ΜΙ έχει αυξητική τάση ενώ ο PRI το αντίθετο. Τα παραπάνω αποτελέσματα κρίθηκαν στατιστικά σημαντικά με 
πιθανότητα σφάλματος p < 5%.
Συμπεράσματα: Οι συγκεντρώσεις της πρεγκαμπαλίνης που χρησιμοποιούνται στην καθημερινή κλινική πράξη φαίνεται να 
έχουν σημαντική επίδραση στο ανθρώπινο γενετικό υλικό in vitro γεγονός που χρήζει περαιτέρω διερεύνησης καθώς δεν 
υπάρχουν αντίστοιχα βιβλιογραφικά δεδομένα και αφορούν έναν μεγάλο αριθμό ασθενών.
Λέξεις Κλειδιά: Πρεγκαμπαλίνη, Γονοτοξικότητα, Χρωματιδιακές ανταλλαγές, Δείκτης ρυθμού πολλαπλασιασμού, Μιτωτικός 
δείκτης.
Επίδραση της πρεγκαμπαλίνης στο ανθρώπινο γενετικό υλικό.
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